Method for feeding of infants with mucoviscidosis

FIELD: medicine.

SUBSTANCE: dry milk product "Pre Nutrilak" is used, in which a portion of water needed for mixture dilution in standard concentration, is replaced with a saline solution of 0.9% sodium chloride, the amount of which depends on the air temperature in the room and the body weight of the child. At the air temperature of 20°C and child weight of up to 5 kg, 60 ml of physiological saline is required to dilute the required amount of dry mixture,10 kg - 90 ml of physiological solution, at the temperature of 25°C and child weight of up to 5 kg - 170 ml of physiological solution, at the child weight of 5-10 kg - 230 ml of physiological solution, at the temperature of 30°C and child weight of up to 5 kg - 280 ml of physiological solution, and at the child weight of 5-10 kg - 450 ml of physiological solution, with feeding frequency of is 7-10 times a day.

EFFECT: method allows to provide the necessary daily dose of sodium chloride and to adapt the therapeutic diet of infants with mucoviscidosis.

4 tbl, 2 ex

 



 

Same patents:

FIELD: veterinary medicine.

SUBSTANCE: treatment is carried out with an aqueous solution of the preparation "Biopag-D" at a concentration of 4-2% by drifting animals through the baths with the solution having the immersion depth up to the carpal joint.

EFFECT: invention enables to treat efficiently and stress-free and prevent treatment of diseases of hooves and dew claws of animals.

3 cl, 5 dwg, 4 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: stimulating the excised liver regeneration is ensured by a 70% hepatectomy into a laboratory animal on the second day of the experiment. A liver regeneration stimulator is presented by L-norvaline administered intragastrically in a daily dose of 10.0 mg/kg every 46 hours for the first 7 days of the experiment.

EFFECT: method provides the effective stimulation of the excised liver regeneration evidenced by reducing the animals' lethality, improved hepatic microcirculation, reduced manifestation of cytolysis and enhanced synthetic function of the liver.

2 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to therapeutic dentistry, and can be used for the local treatment of chronic gingivitis caused by tobacco smoking in young individuals. That is ensured by a preparatory procedure of luminal-dependent chemiluminescence of the oral fluid aiming at a maximum burst and a glow light sum. If the maximum burst falls within the range of 3.3 to 18.15 standard units, whereas the glow light sum ranges from 8.2 to 40 standard units, an antioxidant therapy is conducted by using a transverse gingival mucosa electrophoresis on 5% aqueous propolis by means of jaw electrodes in a tray at a current intensity of 0.5-1 mA and an exposure of 8-10 minutes. A polarity is alternated with a positive pole to be taken the first. The therapeutic course makes 4 procedures every second day. Colgate Propolis Toothpase and Mouthwash are used additionally during 30 days. If the maximum burst is from 0.8 to 1.24 standard units, whereas the glow light sum ranges from 3.34 to 7.5 standard units, a pro-oxidant therapy is required by using an exposure to magnetic infrared laser (MIL) light covering a projection of gums and generated by Optodan laser with a periodontal attachment The exposure parameters: 2-2,000 Hz in segments, 2 minutes per each segment, no more than 12 minutes per 1 procedure. The therapeutic course makes 4 procedures every second day. Parodontax Toothpase and Mouthwash are used additionally during 12 days.

EFFECT: method simplifies and reduces the length of the treatment in the given category of patients.

2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to oxazolopyramidine compounds of formula I, where A represents O; R1 is selected from phenyl or pyrimidine, which are optionally substituted with R11; R2 represents phenyl, which is optionally substituted wby 1-3 ring carbon atoms with similar or different substituents R22, R11 represents halogen; R22 is selected from hydroxy group, (C1-C4)-alkyl, which is optionallysubstituted with 1-3 atoms of fluorine, (C1-C4)-alkyloxy, (C1-C4)-alkyl-S(O)m-; m equals 2. Invention also relates to pharmaceutical composition, which contains formula I compounds, and to method of obtaining formula I compounds.

EFFECT: formula I compounds, intended for activation of EDG-1 receptor and applied for wound healing.

15 cl, 2 tbl, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to oxazolopyramidine compounds of formula (I), where A represents O; X represents (C1-C6)-alkanediyl or (C1-C6)-alkanediyloxy, where oxygen atom of (C1-C6)-alkanediyloxy is bound to group R2; Y represents pyrrolidinyl; R1 represents (C1-C4)-alkyl; R2 represents phenylene, optionally substituted by one or two carbon atoms in ring with similar or different substituent R22; R3 is selected from group, which consists of cycloalkyl-CuH2u-, where u equals 1; radical of saturated 3-10-member monocyclic ring, phenyl or pyridyl, where ring radical is optionally substituted by one or two carbon atoms of ring with substituent R31; R4 represents hydrogen; R22 represents (C1-C4)-alkyl; R31 is selected from group, which consists of halogen and (C1-C4)-alkyl. Invention also relates to (S)-l-[2-(2,6-dimethyl-4-{5-[methyl-(3,3,3-trifluoropropyl)amino]-7-propoxyoxazolo[5,4-d]pyrimidine-2-yl}phenoxy)acetyl]pyrrolidine-2-carboxylic acid, pharmaceutical composition and to method of obtaining compounds of formula (I) .

EFFECT: compounds of formula (I), intended for activation of EDG-1 receptor and applied for wound healing.

16 cl, 2 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: invention relates to veterinary and can be applied in animal-breeding for stimulation of metabolic processes, and growth activity of calves. Medication for stimulation of metabolic processes and growth activity of calves includes succinic acid as energetic stimulator, with application of citric acid as activator of succinic acid, beetroot molasses as carbon component, and methionine and sodium chloride as stimulators of digestion system.

EFFECT: application of invention makes it possible to ensure expressed acceleration of growth energy in early postnatal period.

3 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: cytoflavin is administered into laboratory animals (rats) daily immediately before overheating in an air laboratory thermostat at +40±1-2°C for 45 minutes. The preparation is administered intraperitoneally in a dose of 100 mg/kg of body weight for 14 days.

EFFECT: higher body adaptability by increasing antioxidant activity and reducing a rate of lipid peroxidation products accumulation with underlying thermal exposure.

4 tbl

FIELD: medicine.

SUBSTANCE: minor amputation of the foot with the further necrectomy is performed. After the application of an antimicrobial bandage and drainage, the wound is hermetised from the environment by the creation of a negative pressure above the wound in a combination with drug treatment. The reatment is performed in two steps. At the first step the wound with the antimicrobial bandage and drainage is first hermetised from above with an adhesive film, with the creation and support of the negative pressure not lower than 80 mm Hg. Urokinase 500000 U is additionally introduced daily intravenously by drop infusion per 100 ml of physiological solution, Vessel-Due-F in a dose of 600 LU per 100 ml of physiological solution and VAP 20 - alprostadil in a dose of 40 mcg per 100 ml of physiological solution. In addition Antistax in capsules is introduced to the patient. At the second stage active 24-hour vacuum aspiration with the change of the negative pressure from 10 to 80 mm Hg within a day is carried out. Additionally introduced is Vessel-Due-F in a dose of 1 capsule with 250 LU 2 times per day between meals and Antistax. At the first and second stages Antistax is introduced in a dose of 2 capsules in the morning 30-40 minutes before meal, daily. Duration of each stage constitutes not less than 7 days.

EFFECT: increase of the treatment efficiency due to the complete and timely purification of the wound from pathological exudates, elimination of the progression of the purulent-necrotic process, increase of the regenerative activity of tissues, activation of local immunity, recovery of microcirculation and oxygenation of the affected tissues.

2 cl, 2 ex

FIELD: medicine.

SUBSTANCE: method involves professional oral hygiene is carried out consisting in ultrasonic removal of supra- and subgingival dental deposits and polishing of supragingival teeth. Bite splinting and recovery of dentition integrity may be required. After dissecting a mucoperiosteal flap according to the known technique, an incision area is sanitated by means of a photodynamic therapy (PDT). The PDT is conducted with the use of a diode laser at wave length 660±5 nm and emitting power 0.5-1.0 Wt. The photosensitiser "Photoditasin" in the form of 0.5% gel is introduced by means of a cannula into dental gaps, under the dissected segments of the flap and onto the mucosal tissue for 5 minutes. The photosensitiser is washed out, and the gingival pockets are repeatedly exposed to laser light for 2-3 min in the same environment. Sterile osteoplastic material is introduced into bone defects, and the flap is sutured together.

EFFECT: effective cleansing of the surgical area, eliminating the periodontal inflammation, stimulating tissue osteogenesis and regeneration, stabilising the processes of bone tissue absorption of alveolar interdental septa and preserving the tissues.

2 cl, 1 ex

FIELD: medicine.

SUBSTANCE: to correct pathologic changes in the condition of viable offspring under a cytostatic impact the medication glutoxim is introduced to female rats in a dose of 50 mcg/kg 5 days before and 5 days after the introduction of the cytostatic medication vepesid. The latter is introduced once intravenously in a maximal tolerable dose, equal to 30 mg/kg. It has been established that glutoxim can be applied as means for the correction of pathologic changes in the viable offspring of rats, obtained from coupling 3 months after the cytostatic impact.

EFFECT: application of glutoxim as the means of corrective therapy makes it possible to increase efficiency and reduce its side effects.

6 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry, namely to a method for producing a complex compound of dihydroquercetin with metal ions specified in zinc, copper (II) or calcium possessing antioxidant activity. A method consists in the fact that dihydroquercetin and metal salt is mixed in the dry state in a reactor in certain molar ratio; that is followed by adding water at a certain temperature or ethanol or aqueous-alcoholic solution at a room temperature at the controlled medium acidity; using metal salts containing weak acid anions provides medium pH equal to 5.0-5.6; using the metal salts containing strong acid anions requires reducing pH to 7 by adding an alkaline solution; the reaction is completed almost immediately for the first 5 minutes; the precipitation is filtered in water and/or ethanol; dried in air, then in a drying box to constant weight, and a complex compound is produced. The declared method enables reducing the production costs substantially and cheapening the technological process in achieving the target yield with the preset properties.

EFFECT: method enables producing the stable metal structures and individual powdered substances.

3 cl, 3 dwg, 3 tbl, 12 ex

FIELD: medicine.

SUBSTANCE: invention refers to an antituberculosis drug containing sodium aminosalicylate 2.0-14.0 g and chlorine ions 0.00020-0.00150 g.

EFFECT: preparing the stable and effective antibuberculosis drug.

3 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, particularly to abdominal surgery, and may be applied for preoperative preparation of the patients suffering extensive peritonitis. That is ensured by abdominal paracentesis by the introduction of a catheter through a trocar into an abdominal cavity that is followed by aspiration of the pathological content. Immediately after aspiration of the pathological content, hyperosmolar 10% NaCl is introduced in the abdominal cavity in the amount twice exceeding that of the discharged pathological content. Thereafter, the catheter is clamped for 5-10 minutes, then opened, and the content is evacuated; antiseptic solutions are introduced in the abdominal cavity in the amount twice exceeding that of the hyperosmolar solution. Then the catheter is clamped for 5-10 minutes and opened, the content is evacuated; the abdominal cavity is irrigated with the antibacterial solution.

EFFECT: method provides reducing body intoxification, bacteremia and thereby enhancing the preoperative preparation for compensation of cardiovascular and pulmonary pathologies in somatically severe patients that enables reduced length of the operation and risk of postoperative complications.

5 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, particularly to oncology, and can be applied in treating breast cancer. The method involves introduction of a chlorine photosensitiser (PS) 0.8-1.0 mg/kg in a cubital vein of one arm for 30-40 minutes. Simultaneously, blood in a cubital vein of the other hand is exposed to laser light at wave length matched with maximum absorption of PS light in a radiation dose 200-400 J/cm3. In 1.5 hours after termination of intravenous introduction of the PS and laser light, a number of platinum electrodes are introduced in a growth, a number of optical paths are introduced at 0.5-1 cm from a tumour border; it is followed by electrochemical lysis of the growth at current intensity 30-80 mA for 15-40 minutes; the electrodes are removed, then through the introduced optical paths, laser light is transmitted at wave length matched with maximum absorption of PS light in a dose 200-400 J/cm3. In one day, in the cubital vein of one hand, the chlorine photosensitiser (PS) 0.8-1.0 mg/kg is introduced for 30-40 minutes, and simultaneously, in the cubital vein of the other hand, blood is exposed to laser light at wave length matched with maximum absorption of PS light in a radiation dose 200-400 J/cm3.

EFFECT: use of the invention allows ensuring tumour regresses and performing treatment without radical operation.

1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to medical pharmacology. Pharmaceutical composition with antibacterial activity includes fluoroquinolone, cyclodextrin and hydrochloric acid, and molar ratio of fluoroquinolone to cyclodextrin consists 1:0.5-2.0, composition additionally contains buffer component with the following component ratio, wt %: fluoroquinolone 0.5-10.0; cyclodextrin 3.0-45.0; hydrochloric acid 0.0005-1.0; buffer component 0.1-2.0; water to 100.0.

EFFECT: invention insures high composition stability.

6 cl, 4 dwg, 4 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to pharmaceutical industry and relates in particular to medication for women, which has contraceptive and protective action against inflectional diseases: herpes, HIV infections, viral disease. Medication for vaginal application, possessing contraceptive and protective against inflectional diseases action contains actively-acting components and target base. As actively-acting components medication contains contraceptive, bactericidal, anti-inflammatory preparations, and as target base it contains gel-forming biocompatible polymers and L-lysin hydrochloride with specified component ratio per 1 g. Medication presents gel, ointment, cream, liniment.

EFFECT: medication not only has contraceptive action, but also makes it possible to simultaneously prevent sexually transmitted infection diseases.

3 cl, 6 ex

FIELD: medicine.

SUBSTANCE: invention is related to medicine, in particular to surgery, oncology, gastroenterology and clinical pharmacology and may be used for intubation of thin bowels and intrabowel introduction of medicinal agents and food products to patients in early postoperational period after stomach removal in case of esophageal-thin bowel anastomosis. Multifeeder includes reservoir, batching device, which connected reservoir to probe made of soft plastic, rubber or silicon tube with external diametre of 2-50 mm, oxygen hose, impeller, reducer, and hollow stem with sealing plug, at the end of which there is a mixer. Reservoir is made in the form of thermostat and comprises outlet valve. Oxygen hose is connected via nozzle to body of impeller, which under action of pressure from oxygen stream rotates mixer. At the same time some oxygen arrives to reducer into hollow stem connected to it with cross radial holes, and from it goes to reservoir of thermostat and is mixed with mixture. Batching device is equipped with nozzle and nipple, outlet valve, timer and controller with arrow and vernier with division value of 1 ml. Outlet end of probe is coated with heat insulation material. Working end with length of 40 cm is made of cellulose waxed on two sides with thickness of 50 - 500 mm with longitudinal stiffening ribs along the whole length arranged on internal surface, is filled with gelatin. Out of free butt end of working part there is gelatin protruding in the form of hemisphere with diametre equal to external diametre of probe. Method for enteral introduction of medicines and food after surgery on stomach includes intraoperational introduction of probe-multifeeder into thin bowel through jejunostome, control over location of multifeeder probe with the help of ray-tracing methods of diagnostics, multiple daily infusion of food mixtures homogenised in mixer for 6-7 days through probe, and these mixtures contain sufficient amount of proteins, fats, carbohydrates, vitamins in liquid or semi-liquid state, analysis of introduction intensity and cessation of introduction in case of painful feelings in abdomen, or repeated liquid stool, working end of probe is inserted into stump of duodenum and is moved to its proximal end. Control over location and availability of mixture in duodenum stump is done with the help of ultrasound. Single-time dose of medicine and natural gastric juice in volume of 15-30 ml are additionally added to mixture and heated up to not more than 45°C. Homogenising of mixture is carried out continuously with the help of mixer that operates under action of oxygen stream at higher pressure, dosed and controlled supply of ready mixture into duodenum stump is started after gelatin melting. Volume of mixture needed for complete filling of duodenum stump filling, mixture evacuation from it is controlled. Interval of time required for complete evacuation is identified, and another introduction of mixture is done in portions in this volume with established time interval.

EFFECT: invention improves efficiency and safety of nutrition and treatment due to better quality of mixture preparation, increased accuracy of its introduction and dosing.

2 cl, 1 dwg, 1 ex

FIELD: medicine.

SUBSTANCE: invention concerns medicine and is intended for treatment of inflammatory paradontium diseases at patients with hypothyrosis. On a vestibular surface of mucosa of a gum in the field of the amazed site or if the lesion is generalised - that in the field of roots of 4 or 5 teeth of a corresponding jaw fix size of amplitude of the electromagnetic fluctuations induced in a tissue by external natural electromagnetic fields (EMF) as a result of its bioelectric activity. Initial parametres of a low-frequency impulsive complex modulated electromagnetic field (ICM EMF) are formed according to amplitude. The field is formed with parametres: frequency of modulation in a range from 0.3 to 0.8 Hz, frequency of following of impulses in a range from 3 to 30 Hz, width of a spectrum of harmonious components in a range from 500 Hz to 1 kHz, size of an induction of a magnetic field from 8 to 12 mT. The medical product and a normal saline solution are put by means of applications on a surface of a mucosa of a gum from the oral and vestibular parties and on a surface of teeth. As a medical product it is used clarithromycin in which in addition the 0.05 % solution of chlorhexidine and L-thyroxine is entered. Influence is performed by means of ICM EMF simultaneously on a paradontium tissue and on a spine column. In the course of influence the size of amplitude of electromagnetic fluctuations is constantly supervised and ICM EMF size changes by a feedback principle.

EFFECT: deep penetration of a medical product into area of supporting structures of teeth and creation of depot of a pharmacological preparation of necessary concentration, rendering of the expressed local antiinflammatory, antiedematous, antimicrobial, antibacterial effect at patients with hypothyrosis.

1 ex

FIELD: medicine, surgery.

SUBSTANCE: one should irrigate osseous cavity with 0.5-1.2%-sodium chloride solution saturated with ozone-oxygen mixture for about 5-10 min at ozone concentration being 5000-10000 mcg/l, moreover, before suturing it is necessary to substitute osseous cavity with osseous transplant designed according to the size of osseous cavity. The innovation enables to increase efficiency of antiseptic treatment and, thus, shorten terms of therapy conducted.

EFFECT: higher efficiency.

1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry and represents a combination of leucine source and ω-3 polyunsaturated fatty acid source applicable in therapeutic or preventive treatment of hypercalcemia.

EFFECT: invention provides extending the range of products applicable in the therapeutic or preventive treatment of hypercalcemia.

19 cl, 8 dwg, 2 tbl, 4 ex

Up!